219 related articles for article (PubMed ID: 32430683)
21. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
[TBL] [Abstract][Full Text] [Related]
22. BOP1 confers chemoresistance of triple-negative breast cancer by promoting CBP-mediated β-catenin acetylation.
Li S; Wu H; Huang X; Jian Y; Kong L; Xu H; Ouyang Y; Chen X; Wu G; Yu L; Wang X
J Pathol; 2021 Jul; 254(3):265-278. PubMed ID: 33797754
[TBL] [Abstract][Full Text] [Related]
23. Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer.
Wang H; Wu D; Cai L; Li X; Zhang Z; Chen S
J Cell Mol Med; 2020 Jun; 24(12):6869-6882. PubMed ID: 32394588
[TBL] [Abstract][Full Text] [Related]
24. Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting β-catenin signaling.
Wang J; Qi H; Zhang X; Si W; Xu F; Hou T; Zhou H; Wang A; Li G; Liu Y; Fang Y; Piao HL; Liang X
Biomed Pharmacother; 2018 Dec; 108():724-733. PubMed ID: 30248540
[TBL] [Abstract][Full Text] [Related]
25. First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.
Capasso A; Bagby SM; Dailey KL; Currimjee N; Yacob BW; Ionkina A; Frank JG; Kim DJ; George C; Lee YB; Benaim E; Gittleman B; Hartman SJ; Tan AC; Kim J; Pitts TM; Eckhardt SG; Tentler JJ; Diamond JR
Mol Cancer Ther; 2019 Nov; 18(11):1916-1925. PubMed ID: 31488700
[TBL] [Abstract][Full Text] [Related]
26. MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT.
Nie J; Jiang HC; Zhou YC; Jiang B; He WJ; Wang YF; Dong J
Biosci Biotechnol Biochem; 2019 Jun; 83(6):1062-1071. PubMed ID: 30950326
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
28. HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/β-catenin signaling.
Yu L; Wang C; Pan F; Liu Y; Ren X; Zeng H; Shi Y
Biomed Pharmacother; 2019 Oct; 118():109361. PubMed ID: 31545274
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
30. RNF43 Suppressed Triple-Negative Breast Cancer Progression by Inhibiting Wnt/beta-Catenin Pathway.
Zhu L; Shi H; Li P; Zhang P
Ann Clin Lab Sci; 2023 Jan; 53(1):21-29. PubMed ID: 36889779
[TBL] [Abstract][Full Text] [Related]
31. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
32. CUEDC2 Drives β-Catenin Nuclear Translocation and Promotes Triple-Negative Breast Cancer Tumorigenesis.
Han S; Hao H; Han H; Xue D; Jiao Y; Xie Y; Xu Y; Huangfu L; Fu J; Wang S; Sun H; Li P; Zhou Q
Cells; 2022 Sep; 11(19):. PubMed ID: 36231027
[TBL] [Abstract][Full Text] [Related]
33. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.
Bernemann C; Hülsewig C; Ruckert C; Schäfer S; Blümel L; Hempel G; Götte M; Greve B; Barth PJ; Kiesel L; Liedtke C
Mol Cancer; 2014 Jul; 13():174. PubMed ID: 25033833
[TBL] [Abstract][Full Text] [Related]
34. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
35. Disruption of ZNF334 promotes triple-negative breast carcinoma malignancy through the SFRP1/ Wnt/β-catenin signaling axis.
Cheng Z; Yu R; Li L; Mu J; Gong Y; Wu F; Liu Y; Zhou X; Zeng X; Wu Y; Sun R; Xiang T
Cell Mol Life Sci; 2022 May; 79(5):280. PubMed ID: 35507080
[TBL] [Abstract][Full Text] [Related]
36. Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Ritter A; Hirschfeld M; Berner K; Rücker G; Jäger M; Weiss D; Medl M; Nöthling C; Gassner S; Asberger J; Erbes T
Int J Oncol; 2020 Jan; 56(1):47-68. PubMed ID: 31789396
[TBL] [Abstract][Full Text] [Related]
37. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
38. AKT1
Kabraji S; Solé X; Huang Y; Bango C; Bowden M; Bardia A; Sgroi D; Loda M; Ramaswamy S
Breast Cancer Res; 2017 Aug; 19(1):88. PubMed ID: 28764807
[TBL] [Abstract][Full Text] [Related]
39. DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation.
Xiong Z; Yang L; Li N; Fu J; Liu P; Sun P; Wei W; Xie X
Clin Transl Med; 2022 Dec; 12(12):e1133. PubMed ID: 36536485
[TBL] [Abstract][Full Text] [Related]
40. The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.
Wang W; Rana PS; Markovic V; Sossey-Alaoui K
Breast Cancer Res; 2023 Mar; 25(1):31. PubMed ID: 36949468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
